Psoriasis is an indication for drug development with over 430 pipeline drugs currently active. According to GlobalData, preregistered drugs for Psoriasis have a 94.23% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Psoriasis compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Likelihood of Approval Analysis for Psoriasis

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Psoriasis overview

Psoriasis is a chronic autoimmune skin condition characterized by rapid proliferation of skin cells, leading to thickened, red patches covered with silvery scales. It can occur anywhere on the body but commonly affects the elbows, knees, scalp, and lower back. While the exact cause remains unclear, genetic predisposition and immune system dysfunction play significant roles. Psoriasis often cycles through periods of flare-ups and remission, with triggers including stress, infections, and certain medications. Treatment aims to alleviate symptoms and reduce inflammation through topical treatments, phototherapy, oral medications, and biologic agents. Despite being non-contagious, psoriasis can profoundly impact quality of life due to its visible nature and associated discomfort.

For a complete picture of PTSR and LoA scores for drugs in Psoriasis, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.